AIM
Income statement / Annual
Last year (2023), AIM ImmunoTech Inc.'s total revenue was $202,000.00,
an increase of 43.26% from the previous year.
In 2023, AIM ImmunoTech Inc.'s net income was -$28.96 M.
See AIM ImmunoTech Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$202,000.00 |
$141,000.00 |
$135,000.00 |
$163,000.00 |
$140,000.00 |
$367,000.00 |
$437,000.00 |
$92,000.00 |
$133,000.00 |
$197,000.00 |
Cost of Revenue |
$42,000.00
|
$19.92 M
|
$850,000.00
|
$806,000.00
|
$893,000.00
|
$884,000.00
|
$1.18 M
|
$1.11 M
|
$1.60 M
|
$1.25 M
|
Gross Profit |
$160,000.00
|
-$19.78 M
|
-$715,000.00
|
-$643,000.00
|
-$753,000.00
|
-$517,000.00
|
-$746,000.00
|
-$1.02 M
|
-$1.47 M
|
-$1.05 M
|
Gross Profit Ratio |
0.79
|
-140.3
|
-5.3
|
-3.94
|
-5.38
|
-1.41
|
-1.71
|
-11.04
|
-11.02
|
-5.35
|
Research and Development Expenses |
$10.94 M
|
$6.99 M
|
$7.67 M
|
$5.72 M
|
$4.65 M
|
$4.78 M
|
$4.10 M
|
$5.11 M
|
$8.04 M
|
$8.99 M
|
General & Administrative Expenses |
$21.14 M
|
$13.07 M
|
$8.67 M
|
$8.65 M
|
$7.04 M
|
$6.20 M
|
$6.57 M
|
$7.68 M
|
$7.15 M
|
$9.06 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$21.14 M
|
$13.07 M
|
$8.67 M
|
$8.65 M
|
$7.04 M
|
$6.20 M
|
$6.57 M
|
$7.68 M
|
$7.15 M
|
$9.06 M
|
Other Expenses |
$0.00
|
$1.49 M
|
$2.32 M
|
$1.19 M
|
$866,000.00
|
$277,000.00
|
$3.21 M
|
$2.87 M
|
$1.37 M
|
$1.13 M
|
Operating Expenses |
$32.08 M
|
$20.06 M
|
$16.34 M
|
$14.37 M
|
$11.69 M
|
$10.98 M
|
$10.67 M
|
$12.79 M
|
$15.19 M
|
$18.05 M
|
Cost And Expenses |
$32.12 M
|
$20.06 M
|
$17.19 M
|
$15.18 M
|
$12.58 M
|
$11.86 M
|
$11.85 M
|
$13.90 M
|
$16.78 M
|
$19.30 M
|
Interest Income |
$0.00
|
$629,000.00
|
$67,000.00
|
$219,000.00
|
$89,000.00
|
$46,000.00
|
$88,000.00
|
$129,000.00
|
$364,000.00
|
$665,000.00
|
Interest Expense |
$0.00
|
$0.00
|
$67,000.00
|
$672,000.00
|
$427,000.00
|
$502,000.00
|
$139,000.00
|
$129,000.00
|
$3,000.00
|
$11,000.00
|
Depreciation & Amortization |
$238,000.00
|
-$424,000.00
|
$805,000.00
|
$706,000.00
|
$829,000.00
|
$920,000.00
|
$1.00 M
|
$1.17 M
|
$1.19 M
|
$1.14 M
|
EBITDA |
-$31.68 M |
-$19.87 M |
-$18.26 M |
-$13.02 M |
-$8.15 M |
-$8.41 M |
-$7.12 M |
-$6.33 M |
-$14.25 M |
-$16.74 M |
EBITDA Ratio |
-156.82
|
-124.45
|
-103.44
|
-79.01
|
-76.4
|
-28.05
|
-16.27
|
-134.48
|
-113.5
|
-87.78
|
Operating Income Ratio |
-158
|
-141.3
|
-139.54
|
-92.96
|
-88.88
|
-31.32
|
-26.12
|
-150.04
|
-125.19
|
-96.95
|
Total Other Income/Expenses Net |
$2.95 M
|
$478,000.00
|
-$289,000.00
|
$752,000.00
|
$3.04 M
|
$1.67 M
|
$3.16 M
|
$6.30 M
|
$1.42 M
|
$1.65 M
|
Income Before Tax |
-$28.96 M
|
-$19.45 M
|
-$19.13 M
|
-$14.40 M
|
-$9.53 M
|
-$9.81 M
|
-$8.26 M
|
-$7.50 M
|
-$15.23 M
|
-$17.45 M
|
Income Before Tax Ratio |
-143.38
|
-137.91
|
-141.68
|
-88.34
|
-68.09
|
-26.74
|
-18.9
|
-81.54
|
-114.51
|
-88.58
|
Income Tax Expense |
$0.00
|
$1.64 M
|
$2.39 M
|
$1.86 M
|
$1.29 M
|
$2.19 M
|
$3.35 M
|
$134,000.00
|
$3,000.00
|
$11,000.00
|
Net Income |
-$28.96 M
|
-$21.09 M
|
-$21.51 M
|
-$16.26 M
|
-$10.83 M
|
-$9.81 M
|
-$8.26 M
|
-$7.50 M
|
-$15.23 M
|
-$17.45 M
|
Net Income Ratio |
-143.38
|
-149.55
|
-159.36
|
-99.74
|
-77.33
|
-26.74
|
-18.9
|
-81.54
|
-114.51
|
-88.58
|
EPS |
-0.6 |
-0.44 |
-0.45 |
-0.51 |
-2.97 |
-9.77 |
-12.67 |
-15.13 |
-34.05 |
-48.93 |
EPS Diluted |
-0.6 |
-0.44 |
-0.45 |
-0.51 |
-2.97 |
-9.77 |
-12.67 |
-15.13 |
-34.05 |
-48.93 |
Weighted Average Shares Out |
$48.59 M
|
$48.05 M
|
$47.34 M
|
$31.84 M
|
$3.64 M
|
$1.00 M
|
$651,721.00
|
$495,862.00
|
$447,251.00
|
$356,609.00
|
Weighted Average Shares Out Diluted |
$48.59 M
|
$48.05 M
|
$47.34 M
|
$31.84 M
|
$3.64 M
|
$1.00 M
|
$651,721.00
|
$495,862.00
|
$447,251.00
|
$356,609.00
|
Link |
|
|
|
|
|
|
|
|
|
|